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Differential Activation of Anti-Erythrocyte and Anti-DNA
Autoreactive B Lymphocytes by the Yaa Mutation1
Thomas Moll,* Eduardo Martinez-Soria,* Marie-Laure Santiago-Raber,* Hirofumi Amano,*
Maria Pihlgren-Bosch,* Dragan Marinkovic,† and Shozo Izui2*
An as-yet-unidentified mutation, Y-linked autoimmune acceleration (Yaa), is responsible for the accelerated development of lupus-
like autoimmune syndrome in mice. In view of a possible role for Yaa as a positive regulator of BCR signaling, we have explored
whether the expression of the Yaa mutation affects the development and activation of transgenic autoreactive B cells expressing
either 4C8 IgM anti-RBC or Sp6 IgM anti-DNA. In this study, we show that the expression of the Yaa mutation induced a lethal
form of autoimmune hemolytic anemia in 4C8 transgenic C57BL/6 mice, likely as a result of activation of 4C8 anti-RBC auto-
reactive B cells early in life. This was further supported, although indirectly, by increased T cell-independent IgM production in
spleens of nontransgenic C57BL/6 mice bearing the Yaa mutation. In contrast, Yaa failed to induce activation of Sp6 anti-DNA
autoreactive B cells, consistent with a lack of increased IgM anti-DNA production in nontransgenic C57BL/6 Yaa mice. Our results
suggest that Yaa can activate autoreactive B cells in a BCR-dependent manner, related to differences in the form and nature of
autoantigens. The Journal of Immunology, 2005, 174: 702–709.
I t has been well established that the development of autore-active B cells can be regulated by different mechanisms in-cluding clonal deletion, clonal anergy, and receptor editing in
the bone marrow and peripheral lymphoid organs, depending on
the nature of the autoantigen, its concentration in different sites,
and the affinity of autoantibodies. Because the induction of self-
tolerance is not complete, it has been proposed that dysregulated
and excessive activation of B cells predisposes to the development
of autoantibody-mediated autoimmune diseases, such as systemic
lupus erythematosus (SLE)3 and autoimmune hemolytic anemia
(1). This has been supported by the finding that the production of
anti-DNA autoantibodies is a common feature of genetically ma-
nipulated mice, in which B cells become abnormally hyperrespon-
sive to antigenic stimulation (2–4).
The Y-linked autoimmune acceleration (Yaa) mutation has been
shown to be responsible for the acceleration of the lupus-like au-
toimmune syndrome in BXSB mice and in their F1 hybrids with
NZB or NZW mice (5). Yaa by itself is unable to induce significant
autoimmune responses in mice without an apparent SLE back-
ground (6, 7), whereas it can induce and accelerate the develop-
ment of SLE in combination with autosomal susceptibility alleles
present in lupus-prone mice (8). Analysis of Yaa and non-Yaa
double bone marrow chimeric mice has demonstrated that anti-
DNA autoantibodies were selectively produced by B cells bearing
the Yaa gene, and that T cells from both Yaa and non-Yaa origin
efficiently promoted anti-DNA autoantibody responses (9, 10).
These data suggest that the Yaa defect is functionally expressed in
B cells, but not in T cells. The expression of Yaa in the B cell
lineage is likely responsible for a marked reduction of the marginal
zone (MZ) B cell compartment early in life in spleens of mice
bearing the Yaa mutation (11).
The molecular mechanism of the Yaa mutation in the acceler-
ated development of lupus-like autoimmune syndrome has been
poorly understood. The expression of the Yaa gene in B cells, but
not in T cells, suggests that the Yaa defect is likely to be directly
involved in the excessive activation of B cells. It can be speculated
that the action of the Yaa mutation may be to decrease the thresh-
old for BCR-mediated signaling or to facilitate interactions be-
tween T and B cells, thereby triggering and excessively stimulating
autoreactive B cells (5). This is consistent with a previous report
showing that B cells bearing the Yaa mutation exhibited a hyper-
reactive phenotype, as judged by higher proliferative responses
following stimulation with LPS, anti-IgM, or CD40L (12). To bet-
ter define the molecular basis of the Yaa defect, we determined the
effect of the Yaa mutation on the development and activation of
transgenic autoreactive B cells expressing either 4C8 IgM anti-
RBC or Sp6 IgM anti-DNA. We observed that the Yaa mutation is
unable to inhibit clonal deletion of autoreactive B cells in the bone
marrow. However, it is able to activate 4C8 anti-RBC autoreactive
B cells in the periphery, but not Sp6 anti-DNA B cells, suggesting




C57BL/6 (B6) mice bearing the 4C8 anti-RBC IgMa transgene or the Yaa
mutation have been previously described (7, 13). Sp6 anti-DNA IgMa
transgenic BALB/c mice (BALB.Sp6) were obtained from Dr. A. Rolink
(Pharmazentrum, Basel, Switzerland) (14). B6 mice were purchased from
The Jackson Laboratory. The presence of the 4C8 or Sp6 transgene was
detected by surface staining of peripheral blood B cells with biotinylated
anti-IgMa (RS-3.1). The inheritance of the 4C8 transgene in mice that died
prematurely was assessed by PCR using the following primers: forward
primer (5-CTACGCATTTAGTAGTGACTGG-3) and reverse primer
*Department of Pathology and Immunology, Centre Médical Universitaire, Geneva,
Switzerland; and †Department of Physiological Chemistry, Ulm University, Ulm,
Germany
Received for publication July 8, 2004. Accepted for publication November 1, 2004.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by a grant from the Swiss National Foundation for Sci-
entific Research.
2 Address correspondence and reprint requests to Dr. Shozo Izui, Department of Pa-
thology and Immunology, Centre Médical Universitaire, 1211 Geneva 4, Switzerland.
E-mail address: Shozo.Izui@medecine.unige.ch
3 Abbreviations used in this paper: SLE, systemic lupus erythematosus; MZ, marginal
zone; MLN, mesenteric lymph node; PeC, peritoneal cavity; Ht, hematocrit;
BrMRBC, bromelain-treated mouse RBC.
The Journal of Immunology
Copyright © 2005 by The American Association of Immunologists, Inc. 0022-1767/05/$02.00












(5-TGCAGAGACAGTGACCAGAG-3). Their gender was determined
by PCR for the Y chromosome-specific gene Zfy (15) using the following
primers: forward primer (5-AAGATAAGCTTACATAATCACATGGA-
3) and reverse primer (5-CCTATGAAATCCTTTGCTGCACATGT-3).
Flow cytometric analysis
Flow cytometry was performed using two- or three-color staining of bone
marrow, spleen, mesenteric lymph node (MLN), peritoneal cavity (PeC),
and peripheral blood cells, and analyzed with a FACSCalibur (BD Bio-
sciences). The following Abs were used: anti-B220 (RA3-6B2), anti-IgMa
(RS-3.1), anti-IgMb (MB86), anti-Sp6 Id (20.5) (14), anti-IgDb
(AF-3.33.3.2), PB493 (16), anti-CD21 (7G6), anti-CD23 (B3B4), anti-CD5
(53-7.3), and anti-CD11b (M1/70) mAb. Staining was performed in the
presence of saturating concentration of 2.4G2 anti-FcRII/III mAb.
Determination of hematocrits (Ht)
Blood samples were collected into heparinized microhematocrit tubes and
centrifuged in a microfuge, as described previously (17). Percentage of
packed RBC volume was directly measured after centrifugation.
Serological assays
Serum levels of total IgM were determined by ELISA as described previ-
ously (18). Serum levels of IgMa were determined by ELISA, in which
microtiter plates were coated with rabbit anti-mouse IgM Abs and devel-
oped with alkaline phosphatase-labeled rat anti-mouse IgMa (RS-3.1)
mAb. Results are expressed as micrograms per milliliter in reference to a
standard curve obtained with murine IgM. Serum levels of IgM anti-DNA,
anti-chromatin, and anti-DNP Abs in B6 mice were determined by ELISA
using alkaline phosphatase-labeled anti-IgM (LO-MM-9) mAb, and results
are expressed as titration units (units per milliliter) in reference to a stan-
dard curve established with a serum pool derived from B6 mice treated
with the polyclonal B cell activator LPS. Serum IgM anti-DNA activities
in Sp6 transgenic mice were quantified by ELISA using alkaline phos-
phatase-labeled anti-IgMa (RS-3.1) mAb, and results are expressed as units
per milliliter in reference to a standard curve established with a serum pool
from LPS-injected BALB/c mice. Serum levels of IgM Abs against bro-
melain-treated mouse RBC (BrMRBC) were determined by a flow cyto-
metric assay (19). Briefly, RBC from B6 mice were treated with 1 mg/ml
bromelain (Sigma-Aldrich) for 30 min at 37°C. After washing three times
with 1% BSA-PBS, 20 l of a 25% BrMRBC suspension was incubated
with 100 l of serum samples diluted 1/100 in 1% BSA-PBS for 1 h at 4°C.
Bound autoantibodies against BrMRBC were detected by staining with
biotinylated rat anti-mouse IgM mAb (LO-MM-9) followed by streptavi-
din-PE, and analyzed by FACS. Results are expressed as units per milliliter
in reference to a standard curve established with the median fluorescence
values obtained with serial dilutions of an IgM anti-BrMRBC mAb
(CP8B3D3) (20).
Cell culture
For spontaneous IgM secretion, cell suspensions were prepared from
spleen, MLN, and PeC of Yaa and non-Yaa B6 male mice. Spleen cell
suspensions were treated with Trizma-buffered lysis solution (150 mM
NH4Cl and 20 mM NH2C(CH2OH)3) to eliminate RBC. Triplicates of 10
6
cells were incubated in 200 l of DMEM containing 10% FCS at 37°C for
24 h. IgM levels in culture supernatants were determined by ELISA and are
expressed in nanograms per milliliter.
Enumeration of IgM-secreting cells by ELISPOT
The number of IgM-secreting cells was assessed by ELISPOT analysis as
previously described (21). MULTIscreen HA nitrocellulose-bottomed
plates (Millipore) were coated with 5 g/ml LO-MM-9 anti-IgM mAb
overnight at 37°C. After washing with PBS-0.1% Tween 20 and blocking
with DMEM containing 10% FCS, serial dilutions of spleen cell suspen-
sion, prepared as described for cell culture, were added to the plates and
incubated for 5 h at 37°C. After washing, plates were incubated with al-
kaline phosphatase-conjugated LO-MM-9 overnight at 4°C, washed, and
developed with 5-bromo-4-chloro-3-indolyl phosphate/NBT substrate
(Sigma-Aldrich). Frequencies of IgM-secreting cells were calculated by
counting wells containing between 20 and 100 spots with the use of a
binocular.
Immunohistochemistry and histopathology
Spleens from 8-wk-old B6 male mice of Yaa or non-Yaa genotype were
embedded in Tissue-Tek OCT compound (Miles) and snap-frozen in liquid
nitrogen. Plasma cells were stained using anti-CD138 (syndecan-1) mAb
(281-2; BD Pharmingen) followed by streptavidin-biotinylated HRP com-
plex (Amersham Biosciences). Binding of HRP complex was revealed with
3-amino-9-ethylcarbazo compound. The slides were further counterstained
with hematoxylin to easily distinguish follicles from red pulp. Frozen sec-
tions (10 m) were stained for follicular dendritic cells using purified anti-
CD35 (complement receptor 1) mAb (8C12; BD Pharmingen) followed by
FITC-coupled mouse anti-rat IgG (Jackson ImmunoResearch) and coun-
terstained with Texas Red-labeled goat anti-mouse IgM (Southern Bio-
technology Associates) in the presence of 2.4G2 anti-FcRII/III mAb, as
described previously (22). Major organs, including spleen and liver, were
obtained at autopsy, and histological sections were stained with H&E to
evaluate histopathological changes.
Depletion of CD4 T cells in vivo
B6 mice were treated from birth (during the first 24 h of life) to 4 wk of age
with rat anti-CD4 mAb (GK1.5), as previously described (23). The effi-
ciency of CD4 T cell depletion was evaluated weekly by flow cytometric
analysis of peripheral blood lymphocytes. As a control, mice were simi-
larly treated with polyclonal rat IgG purified from rat serum.
Statistical analysis
Statistical analysis was performed with the Mann-Whitney U test. Proba-
bility values 5% were considered insignificant.
Results
Early activation of 4C8 anti-RBC autoreactive B cells in B6
mice bearing the Yaa mutation
To determine the effect of the Yaa mutation on the development
and activation of autoreactive B cells, we crossed 4C8 transgenic
females with B6 male mice carrying the Yaa mutation (B6.Yaa) or
control male mice, and compared the development of anemia be-
tween Yaa and non-Yaa 4C8 transgenic mice. Among male off-
spring derived from crosses with Yaa-bearing progenitors, we
noted early mortality (before weaning) of a substantial number of
mice. At weaning, the cumulated number of female transgenic
mice was approximately three times higher than that of male trans-
genic littermates bearing the Yaa mutation. When mice found dead
during the first 4 wk of life were genotyped, virtually all of them
were Yaa males carrying the 4C8 transgene. Notably, such an in-
creased early mortality was observed neither in nontransgenic
B6.Yaa mice nor in non-Yaa 4C8 transgenic mice of either sex. To
confirm the early mortality of transgenic Yaa male mice, we geno-
typed mice alive at 3 wk of age, and followed their mortality rates.
As shown (Fig. 1A), essentially all transgenic Yaa male mice died
by 8 wk of age, whereas the mortality rates of transgenic mice
lacking the Yaa mutation and nontransgenic Yaa male mice were
10% during the first 8 wk of life.
At autopsy, we consistently observed massive agglutination of
RBC in spleen and, to a lesser extent, in liver from 4C8 transgenic
B6.Yaa mice that died early in life. These histological lesions were
similar to those observed in mice that died from acute anemia
following an injection of 200 g of 4C8 IgM mAb (17). In con-
trast, only a limited extent of agglutinated RBC was seen in
spleens from non-Yaa transgenic mice. In parallel to the early mor-
tality in transgenic B6.Yaa male mice, there was a decrease in Ht
values in these mice, compared with non-Yaa transgenic controls
( p  0.001; mean Ht values  1 SD: 4C8.Yaa, 26.6  9.4%;
4C8.B6, 39.8  6.7%; nontransgenic controls: 43.7  5.7%; Fig.
1B). These results indicated that the Yaa mutation enhanced 4C8
anti-RBC autoantibody production and caused a lethal anemia in
4C8 transgenic mice.
To determine whether the Yaa mutation could affect the devel-
opment and/or the differentiation of 4C8 transgenic B cells, we
analyzed by flow cytometry the presence of these cells in bone
marrow, spleen, MLN, PeC, and peripheral blood from transgenic
B6.Yaa and control male mice. Despite the development of a more
severe anemia in 4C8 B6.Yaa male mice, transgenic B cells were
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hardly detectable in any of the lymphoid tissues analyzed in these
mice, as in the case of non-Yaa transgenic mice (Fig. 2), in agree-
ment with the previous findings in 4C8 transgenic mice (13, 24,
25). Notably, 4C8 transgenic mice displayed only very limited
amounts of serum IgM, as determined for total IgM and transgenic
IgMa, even in the presence of the Yaa mutation (Table I). These
low concentrations of serum IgM were owed to a very small num-
ber of B cells and a rapid adsorption of 4C8 anti-RBC mAb to
circulating RBC, as previously observed in mice injected with 4C8
mAb (17). These results indicated that the Yaa mutation neither
inhibited clonal deletion of 4C8 anti-RBC autoreactive B cells in
the bone marrow nor promoted their clonal expansion in the
periphery.
Increased spontaneous IgM secretion in young B6 mice bearing
the Yaa mutation
The early mortality due to the development of severe anemia in
young 4C8 transgenic mice bearing the Yaa mutation suggested
that Yaa could induce the activation of B cells very early in life. To
test this possibility, we compared serum IgM levels between non-
transgenic B6.Yaa and non-Yaa male mice at 2, 3, 4, and 8 wk of
age. At 2 wk of age, serum levels of IgM in Yaa and non-Yaa
males were almost comparable (Fig. 3A). However, at 3 wk of age,
B6.Yaa male mice displayed significantly increased levels of IgM
FIGURE 1. Increased mortality in 4C8 IgM anti-RBC transgenic mice
carrying the Yaa mutation due to enhanced autoantibody production. A,
Male 4C8 transgenic (, ) and nontransgenic littermates (E, F) were
genotyped at 3 wk of age, and their mortality in the presence (, F) or
absence (, E) of the Yaa mutation was assessed. B, Ht of 4- to 6-wk-old
4C8.Yaa, 4C8 non-Yaa, and nontransgenic (non-Tg) control male mice.
FIGURE 2. Development of 4C8 transgenic B cells
in different lymphoid tissues of 4- to 6-wk-old
4C8.Yaa, 4C8 non-Yaa, and nontransgenic (non-Tg)
Yaa and non-Yaa male mice. Representative results ob-
tained from four to six mice in each group are shown.
Numbers indicate percentages based on total gated
mononuclear cells. In the bone marrow, 4C8 transgenic
mice both with and without the Yaa mutation showed a
predominant developmental block at the stage of imma-
ture (PB493B220int) B cells and consequently lacked
mature (PB493B220high) B cells. In the periphery, as
illustrated by spleen-cell staining, 4C8 mice hardly
bore any B220 B cells, neither of transgenic (IgMa)
nor of endogenous (IgMb) origin, independent of the
presence or absence of the Yaa mutation. Staining of
mononuclear PeC cells in non-Tg control mice with
mAb against CD5 and CD11b (Mac-1) separated B1a
(CD11bCD5) and B1b (CD11bCD5) cells from T
cells (CD11bCD5) and conventional B2 cells (dou-
ble-negative). All B cell subsets were hardly detectable
in the PeC of 4C8 transgenic mice with or without the
Yaa mutation.
Table I. Serum levels of total IgM and IgM(a) in 4C8 and Sp6
transgenic male mice with or without the Yaa mutation
Mice Transgene Yaa IgMa IgM(a)a
B6 4C8  4.1  2.5 3.2  1.8
B6 4C8  1.9  1.3 1.8  1.2
B6   210  111b NDc
B6   90  34b NDc
(BALB  B6)F1 Sp6  194  69 213  62
(BALB  B6)F1 Sp6  224  51 232  45
(BALB  B6)F1   438  142
b 206  97b
(BALB  B6)F1   213  96
b 97  32b
a Serum concentrations of total IgM and IgM(a) (a allotype) were determined at 4
wk of age for 4C8 transgenic mice and at 6 wk of age for Sp6 transgenic mice. Results
are expressed in micrograms per milliliter (means  1 SD of 8–12 mice in each
group).
b p  0.001.
c Not detectable.
704 ACTIVATION OF AUTOREACTIVE B LYMPHOCYTES BY Yaa












(mean  1 SD, 131  43 g/ml), compared with wild-type male
mice (58  24 g/ml; p  0.001), and the differences remained
significant until 8 wk of age (4 wk, p  0.001; 8 wk, p  0.05).
In contrast, serum levels of total IgG, measured at 8 wk of age,
were not different between Yaa and non-Yaa B6 male mice (Yaa,
11.2  3.3 mg/ml; non-Yaa, 10.1  4.9 mg/ml). Notably, when
B6.Yaa male mice were depleted of CD4 T cells by treatment
with GK1.5 anti-CD4 mAb from birth, they still displayed in-
creased serum levels of IgM, compared with similarly treated non-
Yaa B6 mice (means  1 SD at 4 wk of age: depleted B6.Yaa,
310  131 g/ml; depleted B6, 156  25 g/ml; p  0.05; control
B6.Yaa, 250  24 g/ml; control B6, 122  10 g/ml; p  0.05;
Fig. 3B).
To determine the site of increased IgM secretion in B6 mice
bearing the Yaa mutation, the spontaneous secretion of IgM was
measured by culturing mononuclear cells from spleen, MLN, and
PeC of 8-wk-old B6 male mice with or without the Yaa mutation.
Levels of IgM secreted by Yaa spleen cells during a 24-h culture
were markedly increased, compared with those by non-Yaa spleen
cells (means  1 SD: B6.Yaa, 350  187 ng/ml; B6, 169  92
ng/ml; p  0.001; Fig. 3C). In contrast, no increased secretion of
IgM was observed by MLN and PeC cells from B6.Yaa male mice
(MLN: B6.Yaa, 109  86 ng/ml; B6, 87  70 ng/ml; PeC: B6.Yaa,
295  201 ng/ml; B6, 276  170 ng/ml). Enhanced IgM secretion
by Yaa spleen cells was further confirmed by a 3- to 5-fold in-
crease in the frequency of IgM-secreting cells, as determined by
ELISPOT assay (Fig. 3D). Concordantly, immunohistochemical anal-
ysis of the spleen showed an increased accumulation in B6.Yaa mice
of CD138 plasma cells, located in the red pulp (Fig. 3E).
Because CD11b B1 cells have been considered to be the major
source of serum IgM (26), we determined whether an enhanced
IgM secretion in B6.Yaa male mice was related to a possible in-
crease in B1 cells in the periphery. However, the flow cytometry
analysis did not show any differences in the total number of B1
cells, including both B1 subsets (CD5 B1a and CD5 B1b), in
spleen and PeC between 8-wk-old B6.Yaa and control male mice
(data not shown). It should be stressed that the number of mature
follicular B cells was comparable between B6.Yaa and non-Yaa
male mice, even though the size of the MZ B cell compartment in
B6.Yaa male mice was substantially reduced, as described previ-
ously (11). Furthermore, we analyzed whether the Yaa mutation
promoted an accelerated development of mature B cells in the
spleen, which may predispose to an early activation of B cells.
However, flow cytometric analysis of splenic B cells for different
immature and mature B cell subsets, as well as immunohistochem-
ical analysis of the development of follicular dendritic cells did not
reveal significant differences between B6.Yaa and non-Yaa male
mice at 3 and 5 wk of age, respectively (data not shown).
To determine the specificity of IgM, the production of which
was enhanced by the presence of the Yaa mutation, we tested the
reactivity of serum IgM from 6-wk-old B6.Yaa male mice to dif-
ferent Ags, including DNA, chromatin, DNP, and BrMRBC (Fig.
FIGURE 3. Increase of spontaneous IgM secretion by spleen cells early
in life in B6 mice carrying the Yaa mutation, but without contribution of
CD4 T cells. A, Total serum IgM levels in 2- to 8-wk-old B6.Yaa (F) and
B6 control male mice (E) were determined by ELISA. B, CD4 T cells in
B6.Yaa (, ) and B6 male mice (F, E) were depleted by treatment with
GK1.5 mAb from birth (, F) or mice received polyclonal rat IgG as
control (, E). Total serum IgM levels were determined by ELISA at 4 wk
of age. C, Spleen, MLN, or PeC cells prepared from 8-wk-old B6.Yaa (F,
Œ, f) or B6 control male mice (E, ‚, ) were cultured for 24 h and
spontaneously secreted IgM was quantified by ELISA. A statistically sig-
nificant difference was found only for spleen cells. D, The frequency of
IgM-secreting cells among total spleen cells prepared from adult B6.Yaa or
B6 control male mice was determined by ELISPOT assay. In average,
B6.Yaa male mice contain 17 IgM-secreting cells per 105 total spleen cells,
whereas B6 male mice contain 5 IgM-secreting cells per 105 spleen cells. E,
Frozen sections of spleens from adult B6.Yaa or B6 control male mice were
stained with hematoxylin and anti-CD138 mAb for plasma cells (40).
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4). In parallel to increases in total IgM, sera from B6.Yaa male
mice exhibited significantly increased titers of IgM anti-chromatin,
anti-DNP, and anti-BrMRBC, compared with those from non-Yaa
male mice (means  1 SD: anti-chromatin: B6.Yaa, 14.0  10.5
U/ml vs B6, 4.4  2.7 U/ml; anti-DNP: 11.9  10.6 vs 1.5  1.1;
anti-BrMRBC: 3.8  1.1 vs 2.6  0.2; for all: p  0.001). In
contrast, IgM anti-DNA activities were hardly elevated in B6.Yaa
male mice (B6.Yaa, 5.4  4.0, vs B6, 4.4  1.3).
Lack of activation of Sp6 anti-DNA autoreactive B cells in B6
mice bearing the Yaa mutation
The analysis of the specificity of serum IgM in B6.Yaa and control
male mice suggested that enhanced IgM production occurring in
B6.Yaa mice did not simply reflect an increased polyclonal acti-
vation of B cells, but was possibly related to the specificity of the
BCR. To test this possibility, we determined the effect of the Yaa
mutation on the activation of B cells expressing a transgenic Sp6
IgMa anti-DNA Ab in (BALB.Sp6  B6)F1 mice. Serum levels of
Sp6 IgMa anti-DNA activities were comparable between trans-
genic Yaa and non-Yaa F1 male mice at 6 wk of age (means  1
SD: Yaa: 92.0  44.3 U/ml; non-Yaa: 110.2  74.2 U/ml),
whereas such activities were hardly detectable in sera from non-
transgenic F1 mice (2.5  0.7 U/ml; Fig. 5A). Notably, Sp6 anti-
DNA Abs did not show any significant binding to chromatin (data
not shown). These results were further confirmed by in vitro anal-
ysis for spontaneous secretion of transgenic Sp6 IgMa Abs by Yaa
and non-Yaa spleen cells, as assessed by ELISA and ELISPOT
assays (Fig. 5B). Moreover, no differences in serum levels of total
IgM and transgenic IgMa were found in Sp6 transgenic mice with
or without the Yaa mutation, whereas the potential of the Yaa
mutation to induce increased levels of serum IgM was confirmed
also in nontransgenic F1 controls (Table I).
Flow cytometric analysis on bone marrow and spleen cells
showed that the size of the immature and mature B cell compart-
ments in 8-wk-old Sp6 transgenic males bearing the Yaa mutation
was not different from that of transgenic non-Yaa males, and that
the majority of B cells in spleen expressed the transgenic Sp6 Id
(Fig. 6). However, it should be stressed that mature
PB493B220high, long-lived recirculating B cells were signifi-
cantly reduced in bone marrow from Sp6 transgenic mice, inde-
pendently of the Yaa genotype (means of three mice  1 SD: Yaa,
3.9  0.6%; non-Yaa, 4.7  0.6%), as compared with nontrans-
genic mice (Yaa, 9.5  0.6%; non-Yaa, 8.1  0.9%). This was
consistent with the finding that the percentage of B cells in pe-
ripheral blood was significantly reduced in Sp6 transgenic Yaa
(means of eight mice: 32.8  4.3%) and non-Yaa male mice
(means of nine mice: 28.1  5.1%), compared with nontransgenic
littermates (means of nine mice: Yaa, 58.3  7.5%; non-Yaa,
57.8  8.9%; p  0.001) (Fig. 6). Despite the reduction of the
recirculating B cells, the numbers of mature follicular and MZ B
cells in the spleen of Sp6 transgenic mice were not diminished
compared with those of nontransgenic littermates, as we have pre-
viously shown (11).
Discussion
In the present study, we have demonstrated that the expression of
the Yaa mutation induces a lethal form of autoimmune hemolytic
anemia in 4C8 IgM transgenic mice, likely as a result of an in-
creased activation of anti-RBC autoreactive B cells early in life.
This is consistent with the demonstration of high serum IgM levels
and an increased IgM secretion in spleen from nontransgenic B6
mice bearing the Yaa mutation. In contrast, the Yaa mutation fails
FIGURE 4. Autoreactive specificities of IgM autoantibodies in B6.Yaa
mice. Sera from 6-wk-old B6.Yaa (F) or B6 control male mice (E) were
analyzed by ELISA (anti-DNA, anti-chromatin, anti-DNP) or FACS (anti-
BrMRBC). Serum levels of IgM anti-chromatin, anti-DNP, and anti-
BrMRBC, but not anti-DNA, were significantly increased in B6.Yaa over
B6 mice.
FIGURE 5. No enhancement of the secretion of Sp6 transgenic IgMa
anti-DNA autoantibodies by the Yaa mutation in Sp6 transgenic mice. A,
Sera from 6-wk-old (BALB.Sp6  B6.Yaa)F1 or (BALB.Sp6  B6)F1
male mice, as well as from nontransgenic (non-Tg) controls (with or with-
out the Yaa mutation) were analyzed by ELISA for levels of IgMa anti-
DNA. No statistically significant difference was found between the two
transgenic strains. B, Transgenic IgMa secreted by spleen cells during 24 h
of culture and plasma cell frequencies were determined by ELISA and
ELISPOT, respectively, in (BALB.Sp6  B6)F1 male mice carrying or not
the Yaa mutation. Results from a representative experiment are shown
(three mice per group), and no statistically significant differences were
found.
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to induce activation of Sp6 IgM anti-DNA autoreactive B cells.
The differential effect of the Yaa mutation on these two types of
autoreactive B cells may be related to differences in the form and
nature of the autoantigens involved in stimulation of the respective
B cells.
It is striking to see that essentially all of the 4C8 transgenic mice
carrying the Yaa mutation spontaneously develop a lethal anemia
early in their lives (even before 4 wk of age). The development of
severe anemia in these mice was documented by decreases in Ht
values and histological findings (markedly agglutinated RBC in
red pulp of spleen). The pathogenesis of anemia in the 4C8 trans-
genic Yaa mice is in agreement with our previous finding that the
injection of 4C8 IgM mAb induces anemia as a result of massive
agglutination of RBC in spleen and liver, but is not due to com-
plement-mediated intravascular hemolysis (17).
It is clear that the development of lethal anemia in the context of
the Yaa mutation is not due to failure of clonal deletion of 4C8
anti-RBC autoreactive B cells in the bone marrow. However, we
did not find any sign of expansion of the 4C8 transgenic B cells in
any of the peripheral lymphoid tissues analyzed in Yaa mice. This
suggests that the development of lethal anemia early in life in
4C8 Yaa mice is likely to be a result of a transient activation of
mature 4C8 transgenic B cells. This idea is supported, although
indirectly, by the demonstration that nontransgenic B6.Yaa male
mice had increased serum levels of IgM from 3 wk of age, and
displayed enhanced levels of spontaneous IgM secretion, as well as
increased numbers of IgM-secreting cells in spleen. This is in
agreement with the earlier observation that spleen cells from BXSB.
Yaa male mice exhibit an increased IgM Ab production early in
their lives, compared with those from BXSB females (27).
In the 4C8 transgenic model, it has been repeatedly shown that
B1 cells are the major subset to become activated and secrete 4C8
anti-RBC autoantibodies (25, 28, 29). Because B1 cells largely
contribute to the production of serum IgM without T cell help, an
excessive activation of B1 cells could be partly responsible for an
increased IgM production in B6.Yaa mice. This is consistent with
the finding that B6.Yaa mice had higher serum levels of IgM anti-
BrMRBC Abs, the production of which is largely dependent on the
activation of B1 cells (30). However, we did not find any measur-
able increases in the number of B1 cells in PeC, spleen, and lymph
nodes of 4C8 transgenic Yaa mice developing severe anemia. In
addition, the analysis of nontransgenic Yaa mice failed to show an
expansion of B1 cells in PeC and an increased IgM production by
PeC B cells. Thus, our data rather argue against the idea that B1
cells are the target of Yaa.
We have shown that spleen is the major site for increased IgM
secretion in B6.Yaa mice, and that this process is largely indepen-
dent of the presence of CD4 T cells, because their depletion
FIGURE 6. Development of Sp6 transgenic B cells
in bone marrow (A), spleen (B), and peripheral blood
(C) of 8-wk-old (BALB/c  B6)F1 mice. Representative
results obtained from three mice for bone marrow and
spleen cells, and from eight to nine mice for PBMC are
shown. Numbers indicate percentages based on total
gated mononuclear cells. Even though immature
(PB493B220int) B cells accumulated in the bone mar-
row of Sp6 transgenic mice, independently of the pres-
ence of the Yaa mutation, percentages of total B cells in
the spleen were comparable with those of nontransgenic
controls. In contrast, the percentages of B cells in pe-
ripheral blood were significantly reduced in Sp6 trans-
genic mice with or without the Yaa mutation, consistent
with the finding that recirculating (PB493B220high) B
cells were reduced in bone marrow of these mice. No-
tably, the vast majority of peripheral B cells from Sp6
mice expressed the transgenic Sp6 Id.
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failed to down-modulate hypersecretion of IgM in these mice. Be-
cause MZ B cells are the major subset to secrete IgM without T
cell help in spleen, Yaa may promote the activation of this partic-
ular B cell subset in a T cell-independent manner. However, our
previous analysis showed a markedly reduced number of MZ B
cells in B6.Yaa mice (11). MZ B cells are known to be very rapidly
activated upon stimulation, migrating into the red pulp and differ-
entiating into plasma cells (31, 32). Because we noted an accu-
mulation of plasma cells in the red pulp of Yaa spleens, one can
speculate that the reduction of MZ B cells in Yaa mice may be a
consequence of excessive and continuous activation of MZ B cells
by environmental T-independent Ags, and their migration into the
red pulp and differentiation into plasma cells. In this regard, it is
worth mentioning that we have recently observed an increased
level of IgM secretion in spleen, a diminished MZ B cell com-
partment, but normal numbers of B1 cells in B6 mice congenic for
the New Zealand autoimmunity 2 (Nba2) locus (33), which is a
major locus contributing to lupus susceptibility in NZB mice (34).
In agreement, our preliminary studies have shown that the intro-
duction of Nba2 induced an accelerated development of severe
anemia in the 4C8 transgenic mice. Furthermore, we have previ-
ously detected an increase, instead of a reduction, of the MZ B cell
compartment in Sp6 anti-DNA transgenic Yaa mice (11). This
could be due to the lack of spontaneous activation of these auto-
reactive B cells present in the MZ, and the subsequent failure of
migration into the red pulp, even in the presence of the Yaa mu-
tation. Consistently, our preliminary study has shown that anti-hen
egg lysozyme IgM transgenic mice bearing the Yaa mutation, in
which B cells lack antigenic stimulation, have an increased MZ B
cell compartment, as observed in Sp6 transgenic Yaa mice.
In contrast to 4C8 anti-RBC autoreactive B cells, it is striking to
observe that the Yaa mutation failed to activate Sp6 anti-DNA
autoreactive B cells, as judged by the lack of any increases in Sp6
IgMa anti-DNA Abs in sera and splenocyte culture supernatants.
Differential effect of Yaa cannot be explained by differences in the
functional states of 4C8 and Sp6 B cells, because 4C8 B cells
present in the periphery are expected to be more anergic than the
corresponding Sp6 B cells, because of a more pronounced deletion
of the former cells in the bone marrow. Notably, Sp6 transgenic
mice spontaneously produce substantial amounts of Sp6 anti-DNA
Abs. Because the recirculating pool of mature B cells was mark-
edly diminished in Sp6 transgenic mice, one cannot exclude the
possibility that Yaa differentially activates distinct B cell subpopu-
lations. Alternatively, it may be that the action of the Yaa mutation
is more dependent on BCR specificity, and does not simply reflect
a polyclonal activation of B cells. In fact, when the specificity of
serum IgM in nontransgenic B6.Yaa mice was analyzed, we ob-
served no increase in IgM anti-DNA activities, whereas IgM anti-
chromatin and anti-BrMRBC activities were substantially ele-
vated. As discussed above, Yaa may promote more efficiently the
activation of MZ B cells, which are readily stimulated by partic-
ulate forms of bloodborne Ags in a T cell-independent manner (35,
36). Thus, one can speculate that certain forms of autoantigens,
such as membrane-bound, high-density epitopes, could more effi-
ciently trigger the activation of Yaa-bearing B cells without T cell
help, as may be the case for 4C8 anti-RBC transgenic B cells. This
is in agreement with the observation in young B6.Yaa mice of
spontaneous production of IgM anti-BrMRBC autoantibodies, be-
cause the protease treatment possibly discloses repetitive autoan-
tigenic epitopes on the RBC surface. B cells specific for chromatin
autoantigens may also be more efficiently activated through con-
tact with apoptotic bodies that likely display suitable membrane-
bound autoantigenic determinants. In contrast, this may not be the
case for Sp6 anti-DNA B cells, which are unable to recognize
chromatin.
In the present study, we have shown that the Yaa mutation is
able to activate 4C8 anti-RBC autoreactive B cells, but not Sp6
anti-DNA autoreactive B cells. This suggests that Yaa can activate
autoreactive B cells without T cell help, but dependent on BCR
specificity, and thus likely related to the form and nature of au-
toantigens. However, it should be stressed that the Yaa mutation is
known to promote the production of various autoantibodies of IgG
class, including anti-DNA, in a CD4 T cell-dependent manner
(37). The level of activation induced in naturally occurring DNA-
specific B cells bearing the Yaa mutation upon contact with DNA
autoantigens may still be too weak to induce their differentiation
into IgM producers. However, the presence of Yaa in these B cells
may be sufficient to promote subsequent interaction with autore-
active Th cells. Thus, Yaa could reduce the threshold for B cell
activation following BCR engagement, which may result not only
in triggering a direct activation of B cells upon contact with ap-
propriate autoantigens but also in potentiating a weak interaction
with autoreactive Th cells. This idea is consistent with our previ-
ous observation that Yaa is able to potentiate IgG Ab responses
against foreign Ags only in mice that are genetically (H2-linked)
low-responding, but not high-responding (38). In addition, if Yaa
is indeed involved in the activation of MZ B cells, one can spec-
ulate that Yaa-bearing MZ B cells directly activated by particular
autoantigens may become efficient APCs, thereby promoting sub-
sequent T cell-dependent autoimmune responses. In this regard, it
is worth noting that a recent study has shown that a fraction of
activated MZ B cells can migrate into B cell follicles, and partic-
ipate in the germinal center formation in response to T-dependent
Ags (39). The understanding of the mechanism responsible for the
hyperreactive phenotype of Yaa B cells is of paramount impor-
tance for the elucidation of the molecular abnormality caused by
the Yaa mutation. Ultimately, advances in our understanding of the
nature of the Yaa defect should give important insights into the
development of lupus-like systemic autoimmune disease.
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